Suzetrigine and the Promise of Non-Opioid Pain Relief. At the forefront of Vertex's expansion into pain management is suzetrigine (VX-548), a novel drug candidate with the potential to ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex's stock has risen 18% since last December, ... to believe VK-548's potential in neuropathies is more interesting than its potential in a crowded and complex acute pain management market.

Vertex Pharmaceuticals claimed in a press release that the medication can be used for many types of moderate-to-severe acute pain and has shown no evidence that it is addictive, like opioids ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, ... A Promising Non-Opioid Solution to Acute Pain Management. TipRanks. Oct. 21, 2024, 04:55 AM.

Vertex's candidate, called VX-548, targets NaV1.8 sodium channels, which are thought to play a role in relaying pain signals to the spinal cord from peripheral nerves.

If Vertex does get payer buy-in, Journavx could be an exception to a longstanding, unwritten rule in pain management: fresh therapies take a while to reach patients.

Leerink Partners analyst David Risinger maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $600.00. David Risinger has given his Buy ...

Amid the launch of its non-opioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management.. The new campaign stars former NFL quarterback ...

Vertex is strategically expanding into the pain management sector, Vertex Pharmaceuticals (NASDAQ:VRTX) is a biotechnology company with a strong track record of success in developing treatments ...